Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362111 · ClinicalTrials.gov registry record · Phase 3
Early Treatment of Cytokine Storm Syndrome in Covid-19
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT04362111 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 32 participants.
The verdict
NCT04362111, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
Interventions
- DRUG Normal saline
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362111
The ClinicalTrials.gov registry entry for NCT04362111 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT04362111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362111 about?
NCT04362111 is a clinical study titled "Early Treatment of Cytokine Storm Syndrome in Covid-19". This proposal addresses the problem of preventing the very high mortality and morbidity associated with the development of Cytokine Storm Syndrome (CSS) associated respiratory failure in Covid-19 infection.
What is the current status of trial NCT04362111?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2020-08-01. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT04362111?
The interventions under investigation include: Normal saline (DRUG), Anakinra (DRUG).
Who is sponsoring clinical trial NCT04362111?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.